



A Comprehensive Review of the Role of Complementary and Dietary Medicines in Eradicating *Helicobacter pylori*

Saeid Abdi¹, Sara Ataei², Maede Abroon³, Pantea Majma Sanaye³, Mohammad Abbasnazari⁴ and Amir Farrokhian^{4,*}

¹Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Sciences, Tehran, Iran

²Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, Iran

³School of Pharmacy, Zanzan University of Medical Sciences, Zanzan, Iran

⁴Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

*Corresponding author: Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, No 2660 Vali-e-Asr Aven., P. O. Box: 1991953381, Tehran, Iran. Tel: +98-2188873704, Fax: +98-2188873704, Email: amir.farrokhian@gmail.com

Received 2022 April 16; Accepted 2022 June 18.

Abstract

Antibiotic-resistant *Helicobacter pylori* isolates have become a global concern. The standard triple or quadruple therapies have recently become the most effective protocol for eradicating *H. pylori* in the gastrointestinal tract. There is evidence regarding the impact of different complementary or dietary supplements on *H. pylori* eradication. This review article intended to search electronic bibliographic databases for any clinical studies that evaluated the use of any herbal or dietary supplements to eradicate *H. pylori* up to June 2021. A total of 20 human studies met our criteria and were reviewed. Although some herbal medicines have shown their efficacy and safety in eradicating *H. pylori* in different clinical trials, more randomized blind, placebo-controlled human trials with a large sample size must be performed to extend our knowledge.

Keywords: Medical Databases, Clinical Trials, Herbal Medicines, Nutraceuticals, Gastrointestinal Disorders

1. Context

Eradicating *Helicobacter pylori* has been recommended to treat different upper gastrointestinal disorders. Although combination therapy is suggested for *H. pylori* eradication, using multiple drugs can decrease patients' adherence to pharmacotherapy regimens and may increase the risk of adverse drug reactions (ADRs) (1). Moreover, failure to respond to antibiotics is another concern, and choosing the most efficacious treatment for infected patients has become increasingly important (2).

The popularity of using complementary therapies/dietary supplements to treat gastrointestinal disorders is on the rise. Most studies regarding the effect of complementary therapies in gastrointestinal disorders have been done in vitro (3). The present review article aimed to provide information regarding the use of dietary supplements for eradicating *H. Pylori*, particularly in humans.

2. Evidence Acquisition

A search for human studies published before June 2021 was performed in the SCOPUS, Medline/PubMed, and EM-

BASE databases. All the authors participated in the search process. The authors searched for the terms "*Helicobacter pylori*" with any of the following: "Dietary supplements," "complementary," and "herbal." We focused on the clinical studies published in English (full text or abstract). Data analysis was done by two specialists (a gastroenterologist and a clinical pharmacist) who assessed the title and summary of the search results separately to omit duplicates and case reports. The inclusion criterion was following a human clinical study design to investigate the effect of any herbal medicine or dietary supplement on *H. pylori* eradication. Results of the studies were not the point of selection, and all clinical studies that evaluated the outcome of any complementary or dietary supplement against *H. pylori* eradication were included. Finally, a total of 20 eligible articles were retrieved. The flow of the search is shown in Figure 1.

3. Results and Discussion

3.1. Green and Black Tea (*Camellia sinensis*)

An animal study carried out on Mongolian gerbils by administering green tea catechins solution adsorbed to su-




Figure 1. Search strategy

cralfate reported that the colony count of *H. pylori* was significantly reduced (4). Another study compared a plate of *H. pylori* strains and green tea-embedded discs or control. After incubation, green tea-embedded showed the growth inhibition of *H. pylori*; moreover, the study showed that green tea administration could prevent gastric mucosal inflammation in animal models (5). There is no published clinical trial regarding the effect of green/black tea on eradicating *H. pylori* in the medical literature. Boyanova et al. (6) evaluated the impact of dietary habits on the *H. pylori* infection rate in 150 patients diagnosed with dyspepsia. They examined all the participants endoscopically and with the urea breath test (UBT). The infection rate was less (45.2%) in patients consuming green/black tea one day weekly than in other patients (64.8%). Logistic regression confirmed that green/black tea was correlated with a re-

markably lower *H. pylori* positivity rate (OR, 0.45; 95% CI, 0.21 - 0.95).

3.2. Black Cumin (*Nigella sativa*)

Pharmacological studies, such as Ali et al. (7), suggested different properties of *Nigella sativa* to have anti-inflammatory, antioxidative, and antimicrobial effects. Several studies have mentioned that anti-*H. pylori* effects may be related to numerous ingredients such as thymoquinone, thymol, nigellidine, and carvacrol. The specific environment of the stomach causes the growth of *H. pylori*, and suppressing stomach acid and changing its pH cause *H. pylori* to leave the antrum and make it easier to be eradicated. *Nigella sativa* expresses a potent anti-secretory effect (7-9).

There are two published articles about *N. sativa* administration against *H. pylori* in humans. Salem et al. (10)

evaluated the effect of *N. sativa* in suppressing *H. pylori* in patients diagnosed with Non-Ulcer Dyspepsia (NUD). The study was carried out on 88 patients diagnosed with *H. pylori* using histopathology and the rapid urease test (RUT). The patients were randomly distributed into four groups, as follows: group 1: triple therapy comprising clarithromycin, amoxicillin, and omeprazole; group 2: 1 g *N. sativa* plus omeprazole (40 mg/d); group 3: 2 g *N. sativa* plus omeprazole (40 mg/d); and group 4: 3 g *N. sativa* plus omeprazole (40 mg/d). Eradication rates were evaluated using the fecal antigen test after four weeks. They reported that *H. pylori* elimination was 82.6, 47.6, 66.7, and 47.8% in the groups 1 to 4, respectively. Elimination rates with 2g *N. sativa* and triple therapy were equal statistically, whereas *H. pylori* elimination with other doses was remarkably less than that with triple therapy ($P < 0.05$). Interestingly, the *H. pylori* elimination rate was more with *N. sativa* 2 g/d (66.7%) than with *N. sativa* 3 g/d (47.8%). In the same vein, an in vitro study described a similar consequence, where a lower concentration of *N. sativa* extract exerted more antibacterial effect than a higher concentration of it (11). Symptoms of dyspeptic patients were alleviated in all the groups to a similar extent. They reported that a combination of *N. sativa* plus omeprazole possessed a clinically useful antibacterial effect, comparable to triple pharmacotherapy. In another randomized human study, Alizadeh-Naini et al. (12) determined the effects of adding *N. sativa* to bismuth-based quadruple therapy on *H. pylori* elimination, dyspeptic symptoms, biochemical markers, and quality of life (QoL) in patients infected with *H. pylori*. Fifty-one patients with a diagnosis of NUD were randomized into treatment (bismuth-based quadruple therapy plus 2 g/day *N. sativa*) or placebo (bismuth-based quadruple therapy with 2 g/day placebo) arm for two months. Concentrations of interleukin-8, high-sensitivity C-reactive protein (hs-CRP), malondialdehyde, and QoL were evaluated before and after the trial. Finally, the *H. pylori* elimination rate was more in the *N. sativa* arm against the placebo ($P = 0.01$). Also, the QoL score was more significant in the treatment arm versus the placebo arm ($P < 0.05$). Biochemical markers and dyspeptic symptoms were not different between the two arms. They concluded that the addition of *N. sativa* may have beneficial effects on *H. pylori* eradication and QoL.

3.3. Honey

Boyanova et al. (6) assessed the effect of honey consumption on the *H. pylori* infection rate in 150 patients who suffered from dyspepsia. The patients were evaluated using endoscopy and UBT. They mentioned that the infection rate was lower (50.6%) in those consuming honey more than one day per week than in others (70.8%). They concluded that honey intake was related to a lower *H. pylori* infection rate. Most of the published articles focused on evaluating the effect of honey against *H. pylori* in vitro. In a

systematic review on the in vitro effect of honey against *H. pylori*, Quriasiah et al. (13) searched databases such as Medline via Ovid Medline, Scopus, and ScienceDirect to identify relevant articles published from 2000 to 2018. Associated published data were assessed and chosen based on the criteria on the effects of honey on ulcers in the stomach or duodenum caused by *H. pylori* existence. A total of 53 articles were selected finally. All the articles showed the positive role of honey against ulcers induced by *H. pylori*. Most of the articles reported that a minimum of 10% honey concentration was effective against *H. pylori*. They mentioned the need for future in vitro studies to find the active component and exact mechanism of honey before clinical trials could be done to deliver valid evidence. There is no published article about the net effect of honey on *H. pylori* elimination. Hashem-Dabaghian et al. (14) assessed the effect of a combination of *N. sativa* and honey in eliminating *H. pylori* infections of the stomach. Nineteen participants were requested to intake one teaspoon of the mixture (6 g/day of *N. sativa* as ground seeds and 12 g/day of honey) three times a day after meals for 14 days. *Helicobacter pylori* elimination was determined using UBT at the baseline and after the study. The duration of the study was four weeks. Dyspeptic symptoms were determined at the baseline and after the study and compared. Finally, fourteen participants finished the study. Negative UBT was determined in 57.1% of the patients after providing the intervention. The median and interquartile range (IQR) of total dyspepsia symptoms were remarkably reduced from 5.5 to 1 ($P = 0.005$). All the participants tolerated the *N. sativa* plus honey mixture well, except for one omitted from the study due to mild diarrhea.

3.4. Cranberry (*Vaccinium macrocarpon*)

In vitro studies suggested that cranberry could inhibit *H. pylori* adhesion to the mucosa and reduce colonization of *H. pylori* (15, 16). In a randomized, double-blinded clinical trial, Gotteland et al. (17) evaluated the effect of the regular intake of a mixture of cranberry juice and the *Lactobacillus johnsonii* La1 to eradicate *H. pylori* in infants. Eligible infants, who were *H. pylori* positive, according to UBT, were included in the trial. The infants were divided into four arms: Cranberry juice plus La1 (CB/La1 arm), placebo juice plus La1 (La1 arm), cranberry juice plus heat-killed La1 (CB arm), and placebo juice plus heat-killed La1 (control arm). Cranberry juice (200 mL) and La1 product (80 mL) were administered daily for three weeks, after which a second UBT was done. A third UBT was carried out after 30 days of washout in infants who were negative in the second UBT. Finally, 271 participants completed the treatment course. A different rate of eradication has been shown in four arms: 1.5% in the control arm versus 14.9%, 16.9%, and 22.9% in the La1, CB, and CB/La1 arms, sequentially ($P < 0.01$); the latter group showed a slight but not significant increase

when compared with the other arms. The third UBT was done only in 19 infants who were negative in the second UBT, and *H. pylori* existed in 80% of them. They concluded that the regular intake of cranberry juice or La1 may be useful in treating asymptomatic infants infected with *H. pylori*; however, no additive inhibitory property on *H. pylori* eradication was observed when both agents were simultaneously consumed. Li et al. (18) conducted a human study to determine the dosage effect of daily cranberry intake on *H. pylori* elimination over time in infected persons. A randomized, placebo-controlled blinded trial was conducted on 522 participants infected with *H. pylori*. The study assessed the dose-response effects of proanthocyanidin-standardized cranberry juice, cranberry powder, or identical placebos on eliminating *H. pylori* at two and eight weeks using UBT at 45 days post-intervention. *Helicobacter pylori*-negative rates in placebo, low-proanthocyanidin, medium-proanthocyanidin, and high-proanthocyanidin cranberry juice arms were 13.24%, 7.58%, 1.49%, and 13.85% after 14 days and 7.35%, 7.58%, 4.48%, and 20.00% after eight weeks, sequentially. The intake of high-proanthocyanidin juice twice a day for eight weeks resulted in reduced *H. pylori* infection rate by 20% compared with other dosages and the placebo ($P < 0.05$). The percentage of *H. pylori*-negative patients elevated from two to eight weeks in subjects who consumed 44 mg proanthocyanidin/day juice once or twice daily, showing a statistically notable positive trend over time. In addition, encapsulated cranberry powder doses were not significantly successful at either time. The participants tolerated cranberry juice or powder well in the mentioned trial. The authors concluded that the consumption of proanthocyanidin-standardized cranberry juice twice a day may effectively contribute to *H. pylori* elimination.

3.5. Mastic Gum (*Pistacia lentiscus*)

Before discovering *H. pylori*, some studies intended to show the effects of mastic gum on the healing of gastrointestinal diseases such as Crohn's disease (19). There are only some hints for reducing colonization due to an acidic fraction of this substance. There are two contrasting ideas for mastic gum efficacy against *H. pylori*: (1) ideas stating that positive effects of mastic gum can reduce *H. pylori* colonization, and (2) ideas expressing that anti-*H. pylori* potency is related to its acidic fractions.

Dabos et al. (20) designed a study in which participants were randomly divided into four arms to intake 350 mg of pure mastic gum three times a day (A), 1.05 g of pure mastic gum three times a day (B), 20 mg of pantoprazole twice a day plus 350 mg of pure mastic gum three times a day (C), or a triple therapy consisting of pantoprazole, amoxicillin, and clarithromycin (D). For all the patients, confirmation of *H. pylori* was performed using UBT. The duration of the regimens was 14 days in the A, B, and C arms and 10 days in

the D arm. Five weeks later, *H. pylori* eradication was tested using a repeated UBT. The eradication of *H. pylori* was confirmed in 30% and 38% of the A and B arms, respectively. No patient in the C arm achieved eradication, whereas 77% of patients in the D arm had a negative UBT. There were no statistically significant differences concerning the mean UBT values in A, B, and C arms, although there was a trend in A ($P = 0.08$) and B ($P = 0.064$). Also, the difference was eminent in the D arm ($P = 0.01$). On the whole, mastic gum was tolerated well, and there was no dropout during the trial.

3.6. Olive Oil (*Olea europaea*)

Castro et al. (21) designed and finalized two different pilot human studies to investigate the effect of virgin olive oil on the *H. pylori* elimination rate. In the first trial, 30 volunteers infected with *H. pylori* agreed to intake 30g of washed virgin olive oil for 14 days, and after 30 days, they took 30 g of unwashed virgin olive oil for another 14 days. In the second trial, 30 infected participants received 30 g of a different virgin olive oil for two weeks. In both trials, *H. pylori* infection was assessed using UBT. In the first trial, 27% and 40% of the volunteers became negative by intention to treat per protocol, respectively, while for the second trial, these values were 10% and 11%, sequentially. Thirteen subjects did not tolerate virgin olive oil because of taste and nausea drawbacks, and they dropped out the trial. Castro et al. concluded that the intake of virgin olive oil had little efficacy against *H. pylori*, although further large trials are needed to confirm these preliminary assumptions.

3.7. Licorice (*Glycyrrhiza glabra*)

Licorice potent has antioxidant, anti-cancer, anti-inflammatory, secretin-secreting, and anti-adhesive properties that can be used against *H. pylori*. It can also inhibit DNA gyrase (28). An in vitro study showed the anti-*H. pylori* effect of Licorice (22).

Momeni et al. (22) evaluated the effect of licorice on 60 positive *H. pylori* patients diagnosed with peptic ulcer disease in a randomized clinical trial. Those in the treatment arm received a combination of omeprazole, amoxicillin, metronidazole, and licorice, and those in the control arm received a combination of omeprazole, bismuth subsalicylate, amoxicillin, and metronidazole, which were prescribed for two weeks in each group. Six weeks later, UBT was done on all the patients. The response rate to medical therapy was almost similar (67% in the treatment arm and 57% in the control arm) ($P > 0.05$). They concluded that licorice may be effective as bismuth in eliminating *H. pylori*; therefore, licorice can be substituted with bismuth safely in a quadruple therapy. In a similar small trial by Decker, individuals with peptic ulcer disease positive for *H. pylori* infection (diagnosed by endoscopy and biopsy with positive rapid urease test) were treated with quadruple

therapy or quadruple therapy plus licorice as a substitution for bismuth subsalicylate. After four weeks of medical treatment, eradicating *H. pylori* infection was comparable in both groups (23). Following a clinical trial design, Haji-aghahammadi et al. (24) investigated 120 patients with positive rapid urease tests who were allocated to receive a triple therapy consisting of clarithromycin (control arm) or licorice in addition to the same triple therapy (treatment arm) for two weeks. The eradication rate of *H. pylori* was determined six weeks after ending pharmacotherapy. Response to treatment was 83.3% and 62.5% in the study and control arms, respectively, and the difference was considerable. They concluded that the addition of licorice to the triple therapy consisting of clarithromycin increased *H. pylori* elimination.

3.8. Garlic (*Allium sativum*)

Several studies evaluated the effect of garlic against *H. pylori* in vitro (25, 26). Few clinical trials investigated the effect of garlic on eradicating *H. pylori*. McNulty et al. (27) evaluated the effect of garlic oil on the treatment of patients diagnosed with dyspepsia who were infected with *H. pylori* as a pilot study. The patients were asked to intake a capsule consisting of 4 mg garlic oil four times per day for two weeks. Five dyspeptic patients with positive antibodies against *H. pylori* were confirmed using UBT at the baseline and two weeks later completed the study. If there was a negative UBT at both follow-up evaluations, *H. pylori* elimination would be successful. UBT was used for eradication follow-up. No document of either eradication of *H. pylori* or symptom relief was observed in this trial. They postulated that garlic oil at this dose did not eliminate *H. pylori*. They mentioned that a higher dose of garlic for a longer duration might be effective.

3.9. Cinnamon Extract (*Cinnamomum verum*)

In vitro studies reported the efficacy of cinnamon extract on *H. pylori* growth. This inhibitory effect is due to various compounds such as eugenol, carvacrol, cinnamaldehyde, and anti-inflammatory/antimicrobial activity (28).

In a pilot study, Nir et al. (29) investigated the efficacy of the cinnamon extract in 15 participants infected with *H. pylori* who received either 40 mg of cinnamon extract twice a day or a placebo for 28 days. The colonization rate of *H. pylori* was measured using UBT before and after the intervention. Cinnamon extract was tolerated well, and there was a minimal adverse reaction. At the second UBT, eight patients showed a decrease in the colony count of *H. pylori*, while seven subjects showed an increase in the colony count. In the cinnamon group, the readings in the second UBT increased over the first UBT. The baseline readings were somewhat higher in the control group than in the

other groups, although not significantly. In another randomized clinical trial, Imani et al. (30) evaluated the effect of cinnamon extract on eradicating *H. pylori*. They enrolled 98 healthy volunteers and *H. pylori*-infected patients approved by the endoscopic procedure in the trial. The patients received multiple antibiotic regimens plus cinnamon extract capsules or multiple antibiotic regimens plus a placebo. UBT was done three months after the initiation of the treatment. A notable difference was shown in the *H. pylori* eradication rate, where the rate was 73.47% and 53.06% in the cinnamon and placebo arms, respectively ($P = 0.036$). They concluded that the combined use of cinnamon and antibiotic regimens could increase the rate of *H. pylori* eradication.

3.10. Propolis

It has been postulated that an active phenolic compound of propolis is related to the inhibition of peptide deformylase, which is an essential enzyme for bacterial growth (31). In contrast to various reports regarding the effect of propolis against *H. pylori* in vitro, few clinical trials have investigated this issue. A pilot clinical study on 18 volunteers by Coelho et al. (32) determined that propolis had no effects on the eradication rate. *Helicobacter pylori* infection was confirmed in the participants using histology and UBT. The patients were asked to intake 20 drops from Brazilian green propolis elixir three times a day for one week. Clinical assessment and UBT were carried out 40 days later to evaluate the *H. pylori* eradication rate. According to the findings, 83% of the volunteers did not succeed in suppressing or eliminating *H. pylori*.

3.11. Lycopene

Helicobacter pylori increase the cleavage of Poly [ADP-ribose] polymerase 1, an enzyme that plays a crucial role in DNA recovery. Therefore, *H. pylori* induce apoptosis in gastric epithelial cells. Jang et al. (33) claimed that lycopene inhibited reactive oxygen species and that it could cause modification in the cell cycle of gastric epithelial cells. As a result, lycopene has the potential to treat *H. pylori*-induced gastric diseases.

In a quasi-control trial designed by Shidfar et al. (34), a group of patients received a standard quadruple regimen. The other group received a similar quadruple regimen plus lycopene (30 mg/daily). Thirty days after the intervention, the patients were examined for *H. pylori* elimination using RUT. Although the elimination rate was more in the lycopene group, the bivariate analysis statistically revealed no difference between the two arms.

3.12. Melatonin

A study demonstrated the antioxidative and immunomodulatory activities of melatonin against *H. pylori*. The mRNA expression levels of arylalkylamine-n-acetyl

transferase and acetyl serotonin methyl transferase were assayed in the mucus of the stomach (35). Forkhead box P3 (Foxp3) and transforming growth factor-beta1 (TGF- β 1) are immuno-regulators, which are essential targets in anti-*H. pylori* therapy. Melatonin interferes in inflammatory responses by inhibiting the expression of Foxp3 and TGF- β 1 (36).

There are two published clinical trials about the impact of melatonin in eliminating *H. Pylori* in the medical literature. In a study conducted by Celinski et al. (37), three groups of participants, each including infected patients with gastric or duodenal ulcers, were randomly allocated to intake omeprazole 20 mg twice daily plus placebo (group A), melatonin 10 mg/d (group B), or tryptophan 500 mg/d (group C). All the patients underwent routine endoscopy at the baseline, in which the stomach biopsy was taken for the existence of *H. pylori*. Ulcer alleviation was evaluated using endoscopy at 7, 14, and 21 days after initiating the medications. On day 21, all ulcers were alleviated in participants of the groups B and C, but only 42% of them were cleared in the group A. They concluded that melatonin or tryptophan added to omeprazole could remarkably accelerate the alleviation rate of *H. pylori*-infected chronic peptic ulcers compared to the sole administration of omeprazole. Abdi et al. (38) designed a randomized clinical trial to determine the effect of melatonin addition on the *H. pylori* eradication rate. The trial contained a 14-day quadruple eradication regimen (omeprazole, bismuth subsalicylate, amoxicillin, and metronidazole) supplemented with melatonin 3 mg daily or a comparable placebo. *Helicobacter pylori* elimination rates were 73% in the melatonin arm and 65% in the placebo using intention-to-treat analysis (ITT; n = 118). Elimination rates of per-protocol analysis (PP; n = 98) were 80% and 79% in the melatonin and placebo arms, respectively. The statistical survey did not show any critical difference between the two groups using either ITT or PP analysis (P = 0.74 and P = 0.91, respectively). They concluded that melatonin 3 mg daily did not have any synergistic impact on the *H. pylori* elimination rate.

3.13. Nickel-Free Diet

Nickel is a chemical element that plays a vital role in the existence of *H. pylori*. Nickel activates the urease enzyme, which is essential for metabolism, virulence, and colonization of *H. pylori*. *H. pylori* NikR (HpNikR) is a nickel-responsive transcription factor that regulates urease expression (39). A hypothesis claims that nickel free diet (NFD) can be effective against *H. pylori* infection. It is a type of diet in which foods with high nickel, such as apricots, figs, pears, plums, and asparagus, should be avoided (40).

Campanale et al. (41) compared the *H. pylori* eradication rate of an NFD associated with standard triple therapy and standard triple therapy consisting of lansopra-

zole, clarithromycin, and amoxicillin (LAC) in 52 patients diagnosed with *H. pylori* infection. The patients followed 30 days of an NFD plus a week of LAC regimen starting from day 15 of the diet. A remarkable higher elimination rate was observed in the NFD plus LCA arm (22/26) versus the LCA alone arm (12/26) (P < 0.01). Regarding adverse drug reactions, all regimens were tolerated well, and there was no dropout in either the NFD plus the LCA arm or the LCA arm. Further clinical trials are necessary to confirm this preliminary observation.

3.14. Polyunsaturated Fatty Acids

In vitro studies showed the efficacy of polyunsaturated fatty acids (PUFA) against *H. pylori*'s growth and treatment of duodenal ulcer disease. PUFAs prevent gastrointestinal cancer due to their anti-inflammatory and rejuvenating effects against *H. pylori* (42). It has been shown that PUFAs inhibit Interleukin-8, mRNA, and protein expression in cells infected with *H. pylori* (43).

Few clinical studies investigated the efficacy of PUFA against *H. pylori*. In a human study, 40 patients diagnosed with duodenal ulcers and infected with *H. pylori* received H2 blockers. They were randomized to receive either polyunsaturated fatty acids (PUFA arm) or an identical placebo (control arm). The efficacy of drug regimens is evaluated endoscopically by examining ulcer healing, while the *H. pylori* status was assessed by taking a biopsy from the antrum via RUT and histology. The concentration of prostaglandin E₂ (PGE₂) and leukotriene B₄ (LTB₄) was quantified in the antrum tissue. Despite a remarkable difference in linoleic acid intake (19.9 ± 1.6 g) for the PUFA arm versus controls (6.7 ± 0.8 g) (P < 0.01) and linolenic acid (2.6 ± 0.2 g in the PUFA arm versus 0.6 ± 0.03 g in the control arm) (P < 0.01), there was no remarkable change in either the severity of *H. pylori* elimination or prostaglandin concentrations in either arm after six weeks. An appreciable amount of PUFA does not prevent the stomach colonization of *H. pylori*, nor does it alter the inflammatory features of *H. pylori* gastritis (44). In another clinical trial on *H. pylori*-positive patients (diagnosed with histology and RUT) with mild functional dyspepsia, Frieri et al. (45) evaluated the effect of dietary PUFA supplementation on *H. pylori*. They asked patients to consume two grams of a dietary mixture of fish oil and black currant seed oil daily for eight weeks. The eradication rate of *H. pylori* was determined at the end of the eight weeks. Eight (out of 15) patients (53%) were negative for *H. pylori* after the study period.

4. Conclusions

Table 1 presents the summary of 20 eligible studies regarding the role of supplementary medicine in *H. pylori* eradication. There is a great deal of interest in complementary and herbal medicines globally. However, there is no

consistent evidence to support their efficacy in eradicating *H. pylori*. More high-quality randomized clinical trials are needed in general or for each complementary intervention or usage in the *H. pylori* eradication regimens. We believe that the findings provide an additional benchmark for further trials regarding the effect of dietary medicine on *H. pylori* eradication.

Footnotes

Authors' Contribution: Study concept and design: M.An and A.F; acquisition of data: M.A and P.M.S; drafting of the manuscript: M.A, P.M.S, A.F, and S.At; critical revision of the manuscript for important intellectual content: M.An; administrative and technical support: S.Ab; study supervision: M.An and A.F.

Conflict of Interests: None.

Funding/Support: No funding or support is reported.

References

1. Abbasnazar M, Sahraee Z, Mirahmadi M. The Patients' Adherence and Adverse Drug Reactions (ADRs) which are Caused by Helicobacter pylori Eradication Regimens. *J Clin Diagn Res*. 2013;7(3):462-6. doi: [10.7860/JCDR/2013/4673.2799](https://doi.org/10.7860/JCDR/2013/4673.2799). [PubMed: [23634397](https://pubmed.ncbi.nlm.nih.gov/23634397/)]. [PubMed Central: [PMC3616557](https://pubmed.ncbi.nlm.nih.gov/PMC3616557/)].
2. Hooi JKY, Lai WY, Ng WK, Suen MMY, Underwood FE, Tanyingoh D, et al. Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. *Gastroenterology*. 2017;153(2):420-9. doi: [10.1053/j.gastro.2017.04.022](https://doi.org/10.1053/j.gastro.2017.04.022). [PubMed: [28456631](https://pubmed.ncbi.nlm.nih.gov/28456631/)].
3. Deutsch JK, Levitt J, Hass DJ. Complementary and Alternative Medicine for Functional Gastrointestinal Disorders. *Am J Gastroenterol*. 2020;115(3):350-64. doi: [10.14309/ajg.0000000000000539](https://doi.org/10.14309/ajg.0000000000000539). [PubMed: [32079860](https://pubmed.ncbi.nlm.nih.gov/32079860/)].
4. Takabayashi F, Harada N, Yamada M, Murohisa B, Oguni I. Inhibitory effect of green tea catechins in combination with sucralose on Helicobacter pylori infection in Mongolian gerbils. *J Gastroenterol*. 2004;39(1):61-3. doi: [10.1007/s00535-003-1246-0](https://doi.org/10.1007/s00535-003-1246-0). [PubMed: [14767736](https://pubmed.ncbi.nlm.nih.gov/14767736/)].
5. Stoicov C, Saffari R, Houghton J. Green tea inhibits Helicobacter growth in vivo and in vitro. *Int J Antimicrob Agents*. 2009;33(5):473-8. doi: [10.1016/j.ijantimicag.2008.10.032](https://doi.org/10.1016/j.ijantimicag.2008.10.032). [PubMed: [19157800](https://pubmed.ncbi.nlm.nih.gov/19157800/)]. [PubMed Central: [PMC2694061](https://pubmed.ncbi.nlm.nih.gov/PMC2694061/)].
6. Boyanova L, Ilieva J, Gergova G, Vladimirov B, Nikolov R, Mitov I. Honey and green/black tea consumption may reduce the risk of Helicobacter pylori infection. *Diagn Microbiol Infect Dis*. 2015;82(1):85-6. doi: [10.1016/j.diagmicrobio.2015.03.001](https://doi.org/10.1016/j.diagmicrobio.2015.03.001). [PubMed: [25779680](https://pubmed.ncbi.nlm.nih.gov/25779680/)].
7. Ali BH, Blunden G. Pharmacological and toxicological properties of Nigella sativa. *Phytother Res*. 2003;17(4):299-305. doi: [10.1002/ptr.1309](https://doi.org/10.1002/ptr.1309). [PubMed: [12722128](https://pubmed.ncbi.nlm.nih.gov/12722128/)].
8. Boyanova L, Hadzhiyski P, Kandilarov N, Markovska R, Mitov I. Multidrug resistance in Helicobacter pylori: current state and future directions. *Expert Rev Clin Pharmacol*. 2019;12(9):909-15. doi: [10.1080/17512433.2019.1654858](https://doi.org/10.1080/17512433.2019.1654858). [PubMed: [31424296](https://pubmed.ncbi.nlm.nih.gov/31424296/)].
9. Atapour M, Zahedi MJ, Mehrabani M, Safavi M, Keyvanfar V, Foroughi A, et al. In vitro susceptibility of the Gram-negative bacterium Helicobacter pylori to extracts of Iranian medicinal plants. *Pharmaceutical Biology*. 2009;47(1):77-80.
10. Salem EM, Yar T, Bamosa AO, Al-Quorain A, Yasawy MI, Alsulaiman RM, et al. Comparative study of Nigella Sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. *Saudi J Gastroenterol*. 2010;16(3):207-14. doi: [10.4103/1319-3767.65201](https://doi.org/10.4103/1319-3767.65201). [PubMed: [20616418](https://pubmed.ncbi.nlm.nih.gov/20616418/)]. [PubMed Central: [PMC3003218](https://pubmed.ncbi.nlm.nih.gov/PMC3003218/)].
11. Morsi NM. Antimicrobial effect of crude extracts of Nigella sativa on multiple antibiotics-resistant bacteria. *Acta Microbiol Pol*. 2000;49(1):63-74. [PubMed: [10997492](https://pubmed.ncbi.nlm.nih.gov/10997492/)].
12. Alizadeh-Naini M, Yousefnejad H, Hejazi N. The beneficial health effects of Nigella sativa on Helicobacter pylori eradication, dyspepsia symptoms, and quality of life in infected patients: A pilot study. *Phytother Res*. 2020;34(6):1367-76. doi: [10.1002/ptr.6610](https://doi.org/10.1002/ptr.6610). [PubMed: [31916648](https://pubmed.ncbi.nlm.nih.gov/31916648/)].
13. Quraisiah A, Fazalda A, Alfizah H, Azlina MFN. In vitro Study of Anti-Helicobacter pylori Activity of Honey: A Systematic Review. *Sains Malaysiana*. 2020;49(2):411-20.
14. Hashem-Dabaghian F, Agah S, Taghavi-Shirazi M, Ghobadi A. Combination of Nigella sativa and Honey in Eradication of Gastric Helicobacter pylori Infection. *Iran Red Crescent Med J*. 2016;18(11). e23771. doi: [10.5812/ircmj.23771](https://doi.org/10.5812/ircmj.23771). [PubMed: [28191328](https://pubmed.ncbi.nlm.nih.gov/28191328/)]. [PubMed Central: [PMC5292131](https://pubmed.ncbi.nlm.nih.gov/PMC5292131/)].
15. Zhang L, Ma J, Pan K, Go VL, Chen J, You WC. Efficacy of cranberry juice on Helicobacter pylori infection: a double-blind, randomized placebo-controlled trial. *Helicobacter*. 2005;10(2):139-45. doi: [10.1111/j.1523-5378.2005.00301.x](https://doi.org/10.1111/j.1523-5378.2005.00301.x). [PubMed: [15810945](https://pubmed.ncbi.nlm.nih.gov/15810945/)].
16. Shmueli H, Yahav J, Samra Z, Chodick G, Koren R, Niv Y, et al. Effect of cranberry juice on eradication of Helicobacter pylori in patients treated with antibiotics and a proton pump inhibitor. *Mol Nutr Food Res*. 2007;51(6):746-51. doi: [10.1002/mnfr.200600281](https://doi.org/10.1002/mnfr.200600281). [PubMed: [17487928](https://pubmed.ncbi.nlm.nih.gov/17487928/)].
17. Gotteland M, Andrews M, Toledo M, Munoz L, Caceres P, Anziani A, et al. Modulation of Helicobacter pylori colonization with cranberry juice and Lactobacillus johnsonii La1 in children. *Nutrition*. 2008;24(5):421-6. doi: [10.1016/j.nut.2008.01.007](https://doi.org/10.1016/j.nut.2008.01.007). [PubMed: [18343637](https://pubmed.ncbi.nlm.nih.gov/18343637/)].
18. Li ZX, Ma JL, Guo Y, Liu WD, Li M, Zhang LF, et al. Suppression of Helicobacter pylori infection by daily cranberry intake: A double-blind, randomized, placebo-controlled trial. *J Gastroenterol Hepatol*. 2021;36(4):927-35. doi: [10.1111/jgh.15212](https://doi.org/10.1111/jgh.15212). [PubMed: [32783238](https://pubmed.ncbi.nlm.nih.gov/32783238/)]. [PubMed Central: [PMC8246812](https://pubmed.ncbi.nlm.nih.gov/PMC8246812/)].
19. Kaliora AC, Stathopoulou MG, Triantafyllidis JK, Dedoussis GV, Andrikopoulos NK. Chios mastic treatment of patients with active Crohn's disease. *World J Gastroenterol*. 2007;13(5):748-53. doi: [10.3748/wjg.v13.i5.748](https://doi.org/10.3748/wjg.v13.i5.748). [PubMed: [17278198](https://pubmed.ncbi.nlm.nih.gov/17278198/)]. [PubMed Central: [PMC4066008](https://pubmed.ncbi.nlm.nih.gov/PMC4066008/)].
20. Dabos KJ, Sfika E, Vlatta LJ, Giannikopoulos G. The effect of mastic gum on Helicobacter pylori: A randomized pilot study. *Phytomedicine*. 2010;17(3-4):296-9. doi: [10.1016/j.phymed.2009.09.010](https://doi.org/10.1016/j.phymed.2009.09.010). [PubMed: [19879118](https://pubmed.ncbi.nlm.nih.gov/19879118/)].
21. Castro M, Romero C, de Castro A, Vargas J, Medina E, Millan R, et al. Assessment of Helicobacter pylori eradication by virgin olive oil. *Helicobacter*. 2012;17(4):305-11. doi: [10.1111/j.1523-5378.2012.00949.x](https://doi.org/10.1111/j.1523-5378.2012.00949.x). [PubMed: [22759331](https://pubmed.ncbi.nlm.nih.gov/22759331/)].
22. Momeni A, Rahimian G, Kiasi A, Amiri M, Kheiri S. Effect of licorice versus bismuth on eradication of Helicobacter pylori in patients with peptic ulcer disease. *Pharmacognosy Res*. 2014;6(4):341-4. doi: [10.4103/0974-8490.138289](https://doi.org/10.4103/0974-8490.138289). [PubMed: [25276073](https://pubmed.ncbi.nlm.nih.gov/25276073/)]. [PubMed Central: [PMC4166824](https://pubmed.ncbi.nlm.nih.gov/PMC4166824/)].
23. Decker C. Licorice as an Agent in Helicobacter pylori Quadruple Therapy Regime. *Integr Med Alert*. 2015;18(1).
24. Hajiaghahmohammadi AA, Zargar A, Oveisi S, Samimi R, Reisian S. To evaluate the effect of adding licorice to the standard treatment regimen of Helicobacter pylori. *Braz J Infect Dis*. 2016;20(6):534-8. doi: [10.1016/j.bjid.2016.07.015](https://doi.org/10.1016/j.bjid.2016.07.015). [PubMed: [27614124](https://pubmed.ncbi.nlm.nih.gov/27614124/)].
25. Cellini L, Di Campli E, Masulli M, Di Bartolomeo S, Allocati N. Inhibition of Helicobacter pylori by garlic extract (Allium sativum). *FEMS Immunol Med Microbiol*. 1996;13(4):273-7. doi: [10.1111/j.1574-695X.1996.tb00251.x](https://doi.org/10.1111/j.1574-695X.1996.tb00251.x). [PubMed: [8739190](https://pubmed.ncbi.nlm.nih.gov/8739190/)].
26. Jahani Moghadam F, Navidifar T, Amin M. Antibacterial Activity of Garlic (Allium sativum L.) on Multi-Drug Resistant Helicobacter pylori Isolated From Gastric Biopsies. *Int J Enteric Pathog*. 2014;2(2). doi: [10.17795/ijep16749](https://doi.org/10.17795/ijep16749).
27. McNulty CA, Wilson MP, Havinga W, Johnston B, O'Gara EA, Maslin DJ. A pilot study to determine the effectiveness of garlic oil capsules in the treatment of dyspeptic patients with Helicobacter pylori.

- Helicobacter*. 2001;**6**(3):249-53. doi: [10.1046/j.1523-5378.2001.00036.x](https://doi.org/10.1046/j.1523-5378.2001.00036.x). [PubMed: [11683929](https://pubmed.ncbi.nlm.nih.gov/11683929/)].
28. Tabak M, Armon R, Neeman I. Cinnamon extracts' inhibitory effect on *Helicobacter pylori*. *J Ethnopharmacol*. 1999;**67**(3):269-77. doi: [10.1016/s0378-8741\(99\)00054-9](https://doi.org/10.1016/s0378-8741(99)00054-9).
 29. Nir Y, Potasman I, Stermer E, Tabak M, Neeman I. Controlled trial of the effect of cinnamon extract on *Helicobacter pylori*. *Helicobacter*. 2000;**5**(2):94-7. doi: [10.1046/j.1523-5378.2000.00014.x](https://doi.org/10.1046/j.1523-5378.2000.00014.x). [PubMed: [10849058](https://pubmed.ncbi.nlm.nih.gov/10849058/)].
 30. Imani G, khalilian A, Dastan D, Imani B, Mehrpoya M. Effects of cinnamon extract on complications of treatment and eradication of *Helicobacter pylori* in infected people. *J HerbMed Pharmacol*. 2020;**9**(1):55-60. doi: [10.15171/jhp.2020.08](https://doi.org/10.15171/jhp.2020.08).
 31. Cui K, Lu W, Zhu L, Shen X, Huang J. Caffeic acid phenethyl ester (CAPE), an active component of propolis, inhibits *Helicobacter pylori* peptide deformylase activity. *Biochem Biophys Res Commun*. 2013;**435**(2):289-94. doi: [10.1016/j.bbrc.2013.04.026](https://doi.org/10.1016/j.bbrc.2013.04.026). [PubMed: [23611786](https://pubmed.ncbi.nlm.nih.gov/23611786/)].
 32. Coelho LG, Bastos EM, Resende CC, Paula e Silva CM, Sanches BS, de Castro FJ, et al. Brazilian green propolis on *Helicobacter pylori* infection: a pilot clinical study. *Helicobacter*. 2007;**12**(5):572-4. doi: [10.1111/j.1523-5378.2007.00525.x](https://doi.org/10.1111/j.1523-5378.2007.00525.x). [PubMed: [17760728](https://pubmed.ncbi.nlm.nih.gov/17760728/)].
 33. Jang SH, Lim JW, Morio T, Kim H. Lycopene inhibits *Helicobacter pylori*-induced ATM/ATR-dependent DNA damage response in gastric epithelial AGS cells. *Free Radic Biol Med*. 2012;**52**(3):607-15. doi: [10.1016/j.freeradbiomed.2011.11.010](https://doi.org/10.1016/j.freeradbiomed.2011.11.010). [PubMed: [22178412](https://pubmed.ncbi.nlm.nih.gov/22178412/)].
 34. Shidfar F, Agah S, Ekhlesi G, Salehpour A, Ghourchian S. Lycopene an adjunctive therapy for *Helicobacter pylori* eradication: a quasi-control trial. *J Complement Integr Med*. 2012;**9**:Article 14. doi: [10.1515/1553-3840.1588](https://doi.org/10.1515/1553-3840.1588). [PubMed: [22850072](https://pubmed.ncbi.nlm.nih.gov/22850072/)].
 35. Vielma JR, Bonilla E, Chacin-Bonilla L, Mora M, Medina-Leendertz S, Bravo Y. Effects of melatonin on oxidative stress, and resistance to bacterial, parasitic, and viral infections: a review. *Acta Trop*. 2014;**137**:31-8. doi: [10.1016/j.actatropica.2014.04.021](https://doi.org/10.1016/j.actatropica.2014.04.021). [PubMed: [24811367](https://pubmed.ncbi.nlm.nih.gov/24811367/)].
 36. Luo J, Song J, Zhang H, Zhang F, Liu H, Li L, et al. Melatonin mediated Foxp3-downregulation decreases cytokines production via the TLR2 and TLR4 pathways in H. pylori infected mice. *Int Immunopharmacol*. 2018;**64**:116-22. doi: [10.1016/j.intimp.2018.08.034](https://doi.org/10.1016/j.intimp.2018.08.034). [PubMed: [30173051](https://pubmed.ncbi.nlm.nih.gov/30173051/)].
 37. Celinski K, Konturek S, Slomka M, Cichoż-Lach H, Brzozowski T, Bielanski W, et al. Sui735 Effects of Melatonin and Tryptophan on Healing of Gastric and Duodenal Ulcers With *Helicobacter pylori* Infection in Humans. *Gastroenterology*. 2012;**142**(5):S-491. doi: [10.1016/s0016-5085\(12\)61877-0](https://doi.org/10.1016/s0016-5085(12)61877-0).
 38. Abdi S, Abbasnazari M, Valizadegan G, Kamarei M, Panahi Y, Sarafzadeh F, et al. Does the Addition of Melatonin to Quadruple Therapy Increases the Eradication Rate of *Helicobacter pylori*? A Double-Blind Randomized Clinical Trial. *J Clin Diagn Res*. 2018;**12**(5):FC12 - FC14. doi: [10.7860/jcdr/2018/35589.11543](https://doi.org/10.7860/jcdr/2018/35589.11543).
 39. Jones MD, Li Y, Zamble DB. Acid-responsive activity of the *Helicobacter pylori* metalloregulator NikR. *Proc Natl Acad Sci U S A*. 2018;**115**(36):8966-71. doi: [10.1073/pnas.1808393115](https://doi.org/10.1073/pnas.1808393115). [PubMed: [30126985](https://pubmed.ncbi.nlm.nih.gov/30126985/)]. [PubMed Central: [PMC6130374](https://pubmed.ncbi.nlm.nih.gov/PMC6130374/)].
 40. Minelli M, Schiavino D, Musca F, Bruno ME, Falagiani P, Mistrello G, et al. Oral hyposensitization to nickel induces clinical improvement and a decrease in TH1 and TH2 cytokines in patients with systemic nickel allergy syndrome. *Int J Immunopathol Pharmacol*. 2010;**23**(1):193-201. doi: [10.1177/039463201002300117](https://doi.org/10.1177/039463201002300117). [PubMed: [20378005](https://pubmed.ncbi.nlm.nih.gov/20378005/)].
 41. Campanale M, Nucera E, Ojetti V, Cesario V, Di Rienzo TA, D'Angelo G, et al. Nickel free-diet enhances the *Helicobacter pylori* eradication rate: a pilot study. *Dig Dis Sci*. 2014;**59**(8):1851-5. doi: [10.1007/s10620-014-3060-3](https://doi.org/10.1007/s10620-014-3060-3). [PubMed: [24595654](https://pubmed.ncbi.nlm.nih.gov/24595654/)].
 42. Park JM, Jeong M, Kim EH, Han YM, Kwon SH, Hahm KB. Omega-3 Polyunsaturated Fatty Acids Intake to Regulate *Helicobacter pylori*-Associated Gastric Diseases as Nonantimicrobial Dietary Approach. *Biomed Res Int*. 2015;**2015**:712363. doi: [10.1155/2015/712363](https://doi.org/10.1155/2015/712363). [PubMed: [26339635](https://pubmed.ncbi.nlm.nih.gov/26339635/)]. [PubMed Central: [PMC4538587](https://pubmed.ncbi.nlm.nih.gov/PMC4538587/)].
 43. Lee SE, Lim JW, Kim JM, Kim H. Anti-inflammatory mechanism of polyunsaturated fatty acids in *Helicobacter pylori*-infected gastric epithelial cells. *Mediators Inflamm*. 2014;**2014**:128919. doi: [10.1155/2014/128919](https://doi.org/10.1155/2014/128919). [PubMed: [24987192](https://pubmed.ncbi.nlm.nih.gov/24987192/)]. [PubMed Central: [PMC4060060](https://pubmed.ncbi.nlm.nih.gov/PMC4060060/)].
 44. Duggan AE, Atherton JC, Cockayne A, Balsitis M, Evison S, Hale T, et al. Clarification of the link between polyunsaturated fatty acids and *Helicobacter pylori*-associated duodenal ulcer disease: a dietary intervention study. *Br J Nutr*. 1997;**78**(4):515-22. doi: [10.1079/bjn19970171](https://doi.org/10.1079/bjn19970171). [PubMed: [9389880](https://pubmed.ncbi.nlm.nih.gov/9389880/)].
 45. Frieri G, Pimpo MT, Palombieri A, Melideo D, Marcheggiano A, Caprilli R, et al. Polyunsaturated fatty acid dietary supplementation: An adjunct approach to treatment of *Helicobacter pylori* infection. *Nutr Res*. 2000;**20**(7):907-16. doi: [10.1016/s0271-5317\(00\)00182-2](https://doi.org/10.1016/s0271-5317(00)00182-2).

Table 1. Summary of Human Studies on the Effect of Complementary and Dietary Supplements on *Helicobacter pylori* Eradication

Active Component/ Dose/ Duration	First Author (Year/ Country) (Reference Number)	Putative Anti- <i>Helicobacter pylori</i> Properties	Type of Studies	Number of Patients	Intervention Group	Concurrent Antibiotics Eradication Regimen	Effect
Honey and green black tea/ Dose: N/A/ One day weekly	Boyanova et al. (2015/ Bulgaria) (6)	Polyphenolic for inhibition of the growth of <i>H. pylori</i> for honey	Retrospective study	150	untreated dyspeptic patients	No	Lower <i>H. pylori</i> positivity in patients
<i>Nigella sativa</i> / powder A) 1 g as a capsule of 500mg; B) 2 g as capsule 500mg; C) 3 g as capsule 500mg/ Four weeks	Salem et al. (2010/ Saudi Arabia) (10)	Anti-inflammatory/ Anticancer/ Antimicrobial activity/inhibition of the growth of <i>H. pylori</i>	Randomized, open, clinical trial	88	Nonulcer dyspeptic patients	Yes	Increased eradication rate/Two g of <i>N. sativa</i> has the same effectiveness as triple therapy/One g, and 3g are less than that
<i>N. sativa</i> / 2 g daily/ Eight weeks	Alizadeh-Naini et al. (2020/ Iran) (12)	Antioxidative/Anti- inflammatory effect of thymoquinone on NF- κ B	Randomized, double-blind, placebo-controlled, clinical trial	51	Patients with functional dyspepsia with positive <i>H. pylori</i>	Yes	Significantly increasing the eradication rate/A significant improvement in patients' quality of life/No differences in biochemical markers and dyspepsia between the two groups
The mixture of <i>N.</i> <i>sativa</i> and honey/ a teaspoon (<i>N. sativa</i> 6 g/day; honey 12 g/day)/ three times a day/Two weeks	Hashem-Dabaghian et al. (2016/Iran) (14)	<i>Nigella sativa</i> oil: Antibacterial activity of the phenolic fractions and the urease enzyme inhibition potency of Iranian <i>N. sativa</i> ; Honey: Anti- <i>H. pylori</i> activity	Pilot clinical trial	19	Positive <i>H. pylori</i> (UBI) without a history of peptic ulcer, gastric cancer, or gastrointestinal bleeding	No	<i>Helicobacter pylori</i> eradication in 57% of infected patients/ Significantly reduced score of dyspepsia symptoms
Cranberry juice/ 200 mL and Lactobacillus acidophilus product 80 mL/ Three weeks	Gotteland et al. (2008/ Chile) (17)	Probiotics have been proposed to produce organic acid and bacteriocins capable of inhibiting <i>H. pylori</i> growth / Cranberries have inhibiting activity against <i>H. pylori</i> because it has proanthocyanidins, and cranberry contains polyphenols that are antioxidant and anti-inflammatory	Multicentric, randomized, double-blind, placebo-controlled, clinical trial	295	UBI-positive children	No	No synergism effects observed when simultaneously administering the cranberry juice and Lactobacillus /Temporary <i>H. pylori</i> inhibition by consuming cranberry juice or probiotic/A regular intake of cranberry juice and Lai may be useful in colonizing a symptomatic population
Cranberry juice or juice-based powder/ dosage (44 mg/240-ml serving)/ 2 - 8 weeks	Li et al. (2021/ China) (18)	Proanthocyanidin for suppression of <i>H. pylori</i> infection	Randomized, double-blind, placebo-controlled, clinical trial	522	<i>Helicobacter pylori</i> -positive adults	Yes	Decreased viability of GC cell lines/Reduced esophageal adenocarcinoma/ <i>H.</i> <i>pylori</i> suppression

Pure mastic gum/ 350 mg TID/1.05 mg TID/ 14 days	Dabos et al. (2010 / Greece) (20)	Medicinal product for gastrointestinal upsets with an acidic fraction that can kill <i>H. Pylori</i> in stomach	Randomized controlled clinical trial	52	A patient suffering from an <i>H. pylori</i> infection	Yes	No effect of a combination of mastic gum and pantoprazole on <i>H. pylori</i> Antibacterial activity of mastic gum alone against <i>H. pylori</i> /No effect on the eradication rate
1st study: Washed virgin olive oil/ 30 g/ 14 days followed by unwashed virgin olive oil/ 30 g/14 days; 2nd study: different extra virgin olive oil/ 30 g/14 days	Castro et al. (2012/ Spain) (21)	Antibacterial activity because of phenolic compounds	Pilot clinical trial	1st study: 30; 2nd study: 30	<i>Helicobacter pylori</i> -infected subjects	No	Moderate effectiveness in eradicating <i>H. pylori</i>
D-Reglis/ 380 mg licorice tablet) twice daily/ Four weeks	Momeni et al. (2014/ Iran) (22)	Efficacious for <i>H. pylori</i> eradication/ Anti-inflammatory actions	Randomized, double-blind, placebo-controlled, clinical trial	60	Patients with abdominal pain or dyspepsia and gastric ulcer, duodenal ulcer, gastritis or duodenitis in upper endoscopy and <i>H. pylori</i> positivity	Yes	As efficient as bismuth in <i>H. pylori</i> eradication
Licorice extract/ 380 mg twice daily/ Two weeks	Hajjaghamohammadi et al. (2016/ Iran) (24)	Antioxidant/Anti-cancer/Anti-inflammatory/ Secretory secretin/ Anti-adhesive effect against <i>H. pylori</i> by inhibiting DNA gyrase	Randomized controlled clinical trial	120	Patients suffering from dyspepsia either with peptic ulcer disease (PUD) or non-ulcer dyspepsia (NUD) with a positive rapid urease test	Yes	Higher eradication in patients with PUD/No difference in patients with dyspepsia
Garlic oil/ 4 mg capsule four times per day/Two weeks	McNulty et al. (2001/ UK) (27)	Reduced risk of gastric cancer	Pilot clinical trial	5	Dyspeptic patients with positive serology for <i>H. pylori</i>	No	No evidence of <i>H. pylori</i> eradication and suppression
Alcoholic cinnamon extract/ 40 mg twice daily/ Four weeks	Nir et al. (2000) (29)	Inhibition of the growth of <i>H. pylori</i>	Pilot, randomized, placebo-controlled, clinical trial	23	Patients with positive Campylo Bacter Urease Test (CUT)	No	Did not demonstrate a decline in the colonization rate
Cinnamon extract/ 40 mg capsule twice daily/ 14 days	Imani et al. (2020/ Iran) (30)	Anti-inflammatory/ Antimicrobial activity	Randomized, double-blind, placebo-controlled, clinical trial	98	<i>Helicobacter pylori</i> infected patient	Yes	Increased eradication rate/Reduced complications of <i>H. pylori</i> treatment and increased efficacy of antibiotics
Alcoholic preparation of Brazilian green propolis/ 20 drops three times/ Seven days	Coelho et al. (2007/ Brazil) (32)	Phenolic components inhibiting <i>H. pylori</i> growth	Pilot clinical trial	18	Positive UBT patients	No	No effect on the eradication rate in 83 percent of the patients
Lycopene/ 30 mg daily/ 30 days	Shidfar et al. (2012/ Iran) (34)	Interfering oxidative processes	Parallel group quasi-control trial	54	Patients had been referred to the endoscopy with a positive rapid urease test	Yes	No significant effect on the eradication rate

Melatonin: 5mg; Irrytophan: 250mg/ 21days	Celinski et al. / 2011/ Poland)(37)	Potent endogenous antioxidants/Acting as a common mediator of inter-organ communication between the upper and lower portions of the gut	Randomized, placebo-controlled, clinical trial	42	<i>Helicobacter pylori</i> positive, Gastric or ulcer disease	Yes	Significant effect on the eradication rate (when added to omeprazole treatment)
Melatonin/ 3 mg daily/ 14 days	Abdi et al. (2018/ Iran) (38)	Patient healing lesions like stomatitis, Oesophagitis, Peptic ulcers/ Cytoprotection/ Antioxidant/Free radical scavenger activity	Randomized, double-blind, placebo-controlled, clinical trial	118	Patients with positive rapid urease test via an endoscopy	Yes	No significant effect on the eradication rate in ITT or PP analysis
Nickel-free diet/ N/A/ 30 days	Campanale et al. (2014/ Italy) (41)	Activating Urease and Hydrogenase	Pilot, randomized, controlled, clinical trial	52	Patients who had been diagnosed with <i>H. pylori</i> infection by UBT	Yes	Increased eradication rate
High-PUFA (Efamol)/ Four 500mg capsules Four times daily/ 35 days	Duggan et al. (1997/ England)(44)	PUFAs inhibiting gastric acid secretion while increasing cytoprotective prostaglandins	Randomized, double-blind, placebo-controlled, clinical trial	40	Patients with proven infection with <i>H. pylori</i> / endoscopic evidence of past or present duodenal ulcer disease	Yes	No significant change in either the severity of <i>H. pylori</i> infection or prostaglandin levels
PUFAs/ 2g mixture of fish oil and black currant seed oil/ Eight weeks	Frieri et al. (2000/ Italy) (45)	Inhibiting the growth of <i>H. pylori</i> , increasing PGE production, increasing the effectiveness of the mucosal barrier, and hindering bacterial adhesion to the gastric epithelium	Blinded clinical trial	15	<i>Helicobacter pylori</i> positive patients with mild functional dyspepsia	Yes	No effect on eradication; Modification of cellular membranes of both bacterium and host; Reduced <i>H. pylori</i> virulence